Related Experiment Video
Updated: Jan 10, 2026

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
Published on: November 18, 2019
Prostate cancer: molecular biology of early progression to androgen independence
M D Sadar1, M Hussain, N Bruchovsky
1Department of Cancer Endocrinology, British Columbia Cancer Agency, Vancouver, Canada. msadar@bccancer.bc.ca
Abstract:
To improve the therapy for prostate cancer, it will be necessary to address the problems of progression to androgen independence and the process of metastatic spread of tumour. The complexity of the latter condition is likely to mitigate against the immediate development of relevant therapeutic approaches. However, the basis of androgen independence appears to be a problem of simpler dimensions and more amenable to treatment with current therapeutic technology. Since early tumour progression can be detected by an incomplete prostate-specific antigen (PSA) response to androgen withdrawal therapy, a study of the molecular biology of PSA gene regulation may well provide insight into new methods for preventing or delaying this problem. Mounting evidence suggests that ligand-independent activation of the androgen receptor may be one underlying mechanism of androgen independence. In the absence of androgen, a compensatory increase in the activity of cAMP-dependent protein kinase (PKA) enhances the ability of the androgen receptor to bind to the response elements regulating PSA gene expression. The activation of the androgen receptor through up-regulation of the PKA signal transduction pathway involves the amino-terminus of the androgen receptor, the function of which may be altered either by modifications such as phosphorylation, or through interactions with co-regulators or other proteins. Of therapeutic interest is the fact that this effect can be counteracted experimentally by the anti-androgen, bicalutamide, and clinically by several other similar agents. We speculate that the inhibition of PKA-activated androgen receptor might also be accomplished by decoy molecules that can bind to the relevant activated site on the amino-terminus or competitively interact with proteins recruited by the PKA pathway that are responsible for activating the receptor in the absence of androgen. Such molecules might include small mimetic substances or agents that can gain access to the nucleus of the cell.
Insights
Androgen independence in prostate cancer may stem from increased protein kinase A (PKA) activity, enhancing androgen receptor function without androgen. Targeting this pathway offers new therapeutic strategies for advanced prostate cancer.
Area of Science:
- Oncology
- Molecular Biology
- Endocrinology
Background:
- Prostate cancer progression involves androgen independence and metastasis.
- Androgen independence is a key challenge in prostate cancer therapy.
- Early detection of progression is possible via prostate-specific antigen (PSA) response.
Purpose of the Study:
- Investigate the molecular mechanisms of androgen independence in prostate cancer.
- Identify potential therapeutic targets to prevent or delay androgen independence.
- Explore the role of the androgen receptor and cAMP-dependent protein kinase (PKA) pathway.
Main Methods:
- Studied the molecular biology of PSA gene regulation.
- Examined ligand-independent activation of the androgen receptor.
- Investigated the involvement of the PKA signal transduction pathway.
- Assessed the effect of anti-androgens like bicalutamide.
Main Results:
- Ligand-independent androgen receptor activation is implicated in androgen independence.
- Increased PKA activity enhances androgen receptor binding to PSA gene elements in the absence of androgen.
- The amino-terminus of the androgen receptor is involved in PKA-mediated activation.
- The anti-androgen bicalutamide can counteract this effect.
Conclusions:
- Targeting the PKA-activated androgen receptor pathway presents a novel therapeutic strategy.
- Decoy molecules or agents inhibiting PKA could prevent or delay androgen independence.
- Further research into nuclear-accessible agents is warranted for prostate cancer treatment.
Related Concept Videos
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Targeted Cancer Therapies
There are several types of targeted therapies against...

